Company news

Moleculin Biotech, Inc. news in 2024

Moleculin Biotech, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

December 10, 2024

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML

November 17, 2024

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

November 13, 2024

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

November 11, 2024

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 10, 2024

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

November 4, 2024

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

November 3, 2024

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available

October 16, 2024

Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024

October 6, 2024

Moleculin to Present at Two Upcoming Investor Conferences

October 3, 2024

Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma

September 22, 2024

Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma

September 8, 2024

Moleculin Announces Closing of up to $16.5 Million Public Offering

August 18, 2024

Moleculin Announces Pricing of up to $16.5 Million Public Offering

August 15, 2024

Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 13, 2024

Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial

July 31, 2024

Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML

July 9, 2024

Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial

June 13, 2024

Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress

May 15, 2024

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

May 14, 2024

Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 12, 2024

Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin

May 8, 2024

Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast

May 7, 2024

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data

May 6, 2024

Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024

May 1, 2024

Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin

April 30, 2024

European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)

April 17, 2024

Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties

April 9, 2024

Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML

March 26, 2024

Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial

March 24, 2024

Moleculin Reports Full Year 2023 Financial Results

March 21, 2024

Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast

March 19, 2024

Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3

January 23, 2024

Calls in 2024

Decks in 2024